If you have been reading about 鼻内给药 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-01-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
各国监管态度分化明显。俄罗斯按处方药管理，部分东欧国家留有使用记录；欧盟与美国未批准其作为药物上市，市面流通品通常标注为研究用化学品。身份差异意味着标示含量、纯度与无菌性缺少统一核查。体育领域还牵涉反兴奋剂名录，跨境携带则受目的地药品法规约束。
Semax 是人工设计的七肽，序列为 Met-Glu-His-Phe-Pro-Gly-Pro，骨架取自促肾上腺皮质激素片段 ACTH(4-10)。它于二十世纪八十年代在苏联的分子遗传学研究机构内合成。设计目标是保留该片段与注意力和记忆相关的活性，同时剔除促皮质激素释放等内分泌作用。此后俄罗斯将其登记为药品并进入临床使用。
当时的短肽研究普遍关注能否穿越血脑屏障、在低剂量下产生中枢效应，Semax 属于这一路线。鼻内给药是其主要使用方式，俄语文献报道的适应症涵盖缺血性卒中、短暂性脑缺血发作、认知功能减退以及视神经病变。这些研究大多发表在当地期刊上，样本规模与终点设置同西方试验惯例存在差异，国际同行对其临床证据的强度看法不一。
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | Analogue of the ACTH(4-10) fragment |
| Amino acid sequence | Met-Glu-His-Phe-Pro-Gly-Pro | Single-letter form MEHFPGP |
| Molecular formula | C37H51N9O10S | Free peptide, nominal mass near 814 Da |
| First registration | 1994, Russia | Nasal formulation for neurological indications |
| Typical purity grade | 95% or higher by HPLC | Research material; higher grades used as reference standards |
The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.
Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its design combines the ACTH(4-7) core fragment with a C-terminal Pro-Gly-Pro extension, a modification intended to improve stability and prolong activity. The molecule is hydrophilic, carries no lipid chains or glycosylation, and has a theoretical mass just over 810 daltons in its free form. All seven residues are proteinogenic amino acids, so no non-natural building blocks appear in the backbone. A free N-terminal methionine and C-terminal proline define the unmodified parent peptide.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was derived from the ACTH(4-10) fragment, a short segment of adrenocorticotropic hormone that lacks the hormonal activity associated with the full-length peptide. Researchers at the Institute of Molecular Genetics in Moscow developed the compound during the 1980s. It has been registered as a pharmaceutical product in Russia and several neighbouring countries, where it is supplied as a nasal solution, and it is also sold internationally as a research chemical.
The proposed mechanism centres on neurotrophic signalling rather than direct receptor activation. Semax is reported to increase expression of brain-derived neurotrophic factor and nerve growth factor in several brain regions, and to shift the balance between excitatory and inhibitory neurotransmitter systems. Interaction with melanocortin receptors has been suggested because of the parent ACTH fragment. Many of these findings come from rodent studies, and the extent to which they translate to human physiology remains an open question.
Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.
Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.
Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its chain combines the first seven residues of corticotropin with a C-terminal proline-glycine-proline extension, a modification intended to slow enzymatic breakdown. The free peptide has a molecular mass near 813.9 daltons. It belongs to the class of ACTH-derived fragments studied for central nervous system activity rather than for adrenal steroid stimulation. This structural relationship to a natural hormone fragment is the usual starting point for describing the compound in the literature.
Development took place during the 1980s at institutes of the Russian Academy of Sciences, where peptide fragments of ACTH were screened for cognitive and neuroprotective effects. The compound received regulatory approval in Russia as a nasal preparation, marketed for conditions such as ischemic stroke, transient ischemic attacks, and optic nerve disorders. Registration in other countries has not followed. Most published clinical reports originate from a small number of Russian research groups, and independent replication outside that setting remains limited. The regulatory status therefore differs sharply between Russia and the rest of the world.
Laboratory work points toward modulation of neurotrophic signaling, particularly expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal tissue. Studies also describe effects on monoamine turnover, inflammatory mediators, and oxidative markers. These observations come mainly from animal models and cultured cells, so the causal chain in humans is not firmly established. Whether the reported molecular changes translate into measurable clinical benefit is an open question. Reviews generally present the mechanism as plausible rather than demonstrated.
Diphenhydramine, while traditionally known as an antagonist, acts primarily as an inverse agonist of the histamine H1 receptor. It is a member of the ethanolamine class of antihistaminergic agents. By reversing the effects of histamine on the capillaries, it can reduce the intensity of allergic symptoms. It also crosses the blood–brain barrier and inversely agonizes the H1 receptors centrally. Its effects on central H1 receptors cause drowsiness. Diphenhydramine is a potent antimuscarinic (a competitive antagonist of muscarinic acetylcholine receptors) and, as such, at high doses can cause anticholinergic syndrome. The utility of diphenhydramine as an antiparkinson agent is the result of its blocking properties on the muscarinic acetylcholine receptors in the brain. Diphenhydramine also acts as an intracellular sodium channel blocker, which is responsible for its actions as a local anesthetic. Diphenhydramine has also been shown to inhibit the reuptake of serotonin. It has been shown to be a potentiator of analgesia induced by morphine, but not by endogenous opioids, in rats. The drug has also been found to act as an inhibitor of histamine N-methyltransferase (HNMT).
12-14 August On the 12th the 1st Battalion, 7th Marines were attacked by the PAVN 8th and 9th Battalions, 90th Regiment and 1st Battalion, 368E Artillery (Rocket) Regiment in the "Arizona Territory". The Marines repelled the attack and killed 203 PAVN and captured two and 72 weapons in a daylong battle. On the 13th the Marines engaged a 100 strong PAVN force in a seven hour battle, killing 73 for the loss of five Marines killed. On the 14th the PAVN attacked again losing 13 killed and ten weapons.
The most common cause of CH is dysgenesis of the thyroid gland After many years of newborn screening, the incidence of CH worldwide had been estimated at 1:3600 births, with no obvious increases in specific ethnic groups. Recent data from certain regions have shown an increase, with New York reporting an incidence of 1:1700. Reasons for the apparent increase in incidence have been studied, but no explanation has been found. Classic CAH, the disorder targeted by newborn screening programs, is caused by a deficiency of the enzyme steroid 21-hydroxylase and comes in two forms – simple virilizing and a salt-wasting form. The incidence of CAH can vary greatly between populations. The highest reported incidence rates are among the Yupic Eskimos of Alaska (1:280) and on the French island of Réunion (1:2100).
== History == The initiative was established in 2006 through a tripartite collaboration involving Cartier (jeweler), the international management consulting firm McKinsey & Company, and the INSEAD international business school. The program was designed to target discrepancies in international venture capital, where women entrepreneurs encounter substantial barriers in closing early-stage seed round funding. Over its two decades of operation, the program expanded from its foundational baseline of five regional categories to nine distinct geographic regions. In 2021, the initiative introduced its first thematic categories to incorporate technical innovations outside of regional boundaries. To mark its 2 decade anniversary in 2026, the program relocated its annual awards summit to Bangkok, Thailand, selecting a cohort of 30 global fellows.
DiCaprio earned nominations for a Golden Globe and a BAFTA Award for the film. It broke the record for the most views (152 million hours) in a single week in Netflix history. DiCaprio next starred in Scorsese's crime drama Killers of the Flower Moon (2023) based on the book of the same name by David Grann, for which he was paid $30 million. Initially signed for the heroic part of FBI agent Thomas Bruce White Sr., DiCaprio insisted on playing the morally complex role of murderer Ernest Burkhart, leading to extensive script rewrites. Declaring it the best performance of DiCaprio's career, IndieWire's David Ehrlich wrote that "his nuanced and uncompromising turn as the cretinous Ernest Burkhart mines new wonders from the actor's long-standing lack of vanity". He received another Golden Globe nomination for his performance. DiCaprio next starred in Paul Thomas Anderson's film One Battle After Another (2025), alongside Sean Penn and Regina Hall. For his role as a washed-up ex-revolutionary, he received his seventh Academy Award acting nomination. In December 2025, DiCaprio confirmed he has been cast in an undisclosed role in Michael Mann's planned sequel to the 1995 film Heat. As of February 2026, DiCaprio began shooting What Happens at Night, helmed by Martin Scorsese, also starring Jennifer Lawrence and Mads Mikkelsen.
Sources: en.wikipedia.org
Some women complain of a "small penis" when the trim procedure is performed, owing to the un-addressed clitoral hood tissue and completely removed (amputated) labia minor. Most plastic surgeons do not perform this procedure, and instead favor the extended wedge approach, which is technically more demanding, but produces a more natural result and is able to create a natural and proportioned appearance to the vulva. Reconstructive procedures are often required after the trim (amputation) labiaplasty.
Traditional markets, called pasars (including pasar malam and pasar pagi), are found across in Indonesia in both urban and rural areas. They face increasing competition from supermarkets as well as e-commerce companies like Shopee and Tokopedia. As of 2020, there are 12.3 million traders across 13,450 traditional markets in Indonesia. In 2016, the Indonesia government's policy to stabilise beef prices required importers to sell cheaper-priced meats in traditional markets instead of in supermarkets and hypermarkets. In Greater Jakarta, Indian buffalo meat is predominantly sold in traditional markets, with limited market penetration from supermarkets and hypermarkets as of 2018. In contrast, only 7% of consumers in Jakarta purchase Australian beef from supermarkets in 2018. In 2018, Indonesian market vendors that import goods expressed concerns over the decrease in value of the Indonesian rupiah. Traditional markets throughout Indonesia have undergone major renovations in the 2010s under a government program. In 2018, the first modernised traditional market opened in Jakarta with a laboratory as well as freezing and refrigeration facilities. Through June 2020, health protocols and mobility restrictions from the COVID-19 pandemic in Indonesia resulted in a 65% reduction in revenue for market traders, according to the Traditional Market Traders Association (IKAPPI). In mid-2020, traditional markets in several provinces accounted for several major clusters of COVID-19 cases.
Salting is the preservation of food with dry edible salt. It is related to pickling in general and more specifically to brining, (preparing food with brine, that is, salty water), and is one form of curing. It is one of the oldest methods of preserving food, and two historically significant salt-cured foods are salted fish (usually dried and salted cod or salted herring) and salt-cured meat (such as bacon). Vegetables such as runner beans and cabbage are also often preserved in this manner. Salting is used because most bacteria, fungi and other potentially pathogenic organisms cannot survive in a highly salty environment, due to the hypertonic nature of salt. Any living cell in such an environment will become dehydrated through osmosis and die or become temporarily inactivated. Fine grained salts were more expensive but also absorbed moisture faster than coarse salt.
== NatB phenotypes == Studying the effect of mutations in the NAA20 gene and the NAA25 gene in human cells have shown similar cellular phenotypes, among others that downregulating NatB activity reduce the cytoskeleton stability by affecting the actin microfilaments and focal adhesion. By knocking out either the NAA20 or NAA25 gene, the same was observed in human cells as in yeast cells; reduction of actin microfibrils, as well as reduction of focal adhesions in the cell. The findings in this study also indicated that human NatB is more likely to acetylate MQ- protein N-termini at a higher rate than yeast NatB. Meaning that NatB is important for maintaining the structure and movement of the cell. NatB might also be linked to proteins involved in cellular growth, as knockdown of both NAA20 and NAA25 resulted in a decrease in cell proliferation. Knocking down either NAA20 or NAA25 however resulted in decrease in cell proliferation, more cell death or cells locked in the interphase stage (G0/G1), respectively. NatB has also been studied in mouse embryonic fibroblasts (MEFs) cells by knocking out the NAA20 gene, and as in human and yeast, cell proliferation decreased, as well as actin cytoskeleton and disorganization of and decrease in focal adhesion. DNA replication was also negatively affected, probably causing senescence in the cells.
Sources: en.wikipedia.org
Registered medical products are most often 0.1% nasal drops. Research suppliers ship lyophilized powder, usually in milligram quantities, which is dissolved before use. The active peptide is the same in both cases; presentation and excipients differ.
No. The peptide is synthetic, although it is modelled on a fragment of a naturally occurring hormone. ACTH(4-10) is generated when ACTH is cleaved, but the Pro-Gly-Pro extension is not a known endogenous sequence. It is therefore a designed analogue rather than a natural metabolite.
The label reflects reported effects on attention, memory and recovery after neurological injury in regional clinical reports. Those reports are mostly small and have not been widely replicated outside the region. The classification is descriptive and does not imply a single defined mechanism.
不存在。它是依据 ACTH 的一段序列人工设计的分子，天然蛋白质中找不到与之完全相同的七肽。名称属于研究代号，而非天然物质名。